Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission

Fig. 3

Same model result as in Fig. 2, but with tOPV and bOPV take rates calculated directly from cumulative 2-dose seroconversion estimates reported by Sutter et al. (2010)[27] (see Table 1). a Population immunity to serotype 1 poliovirus transmission. b Population immunity to serotype 2 poliovirus transmission. c Population immunity to serotype 3 poliovirus transmission

Back to article page